JAGX - Peru's Coca Leaf Will Be Used For Research Toward Treating ADHD Learn The Details | Benzinga
Magdalena Biosciences, Jaguar Health (NASDAQ: JAGX) and Filament Health (OTCQB: FLHLF) recently formed a joint venture to develop novel plant-based medicines for mental health indications. They completed the import of Peruvian coca leaf to Canada to be assessed for the potential treatment of attention-deficit/hyperactivity disorder (ADHD) in adults.
Once understood as a childhood disorder, ADHD commonly persists and affects around 50-65% of adults (5.2% of U.S. adults between 18 and 44.) Current treatments face challenges, with 20-50% of adult patients unresponsive or intolerant to them; new therapeutics in development show promise but have significant side effects. Meanwhile, botanical drugs are believed to offer potential advantages, including improved safety profiles.
The import of coca leaves was authorized by the Peruvian Health Authority (DIGEMID) and will head to Filament’s facility, Psilo Scientific for initial research purposes for ADHD, extending to depression and anxiety.
The cargo was produced by ENACO, reportedly ...